Kyprolis

FDA gives full approval to Amgen blood cancer drug
FDA gives full approval to Amgen blood cancer drug
Yahoo/Reuters
FDA
Amgen
Kyprolis
blood cancer
Flag link:
Here’s Why Amgen Shares are Likely to Rise this Year
Here’s Why Amgen Shares are Likely to Rise this Year
Bidness, ETC
Amgen
R&D
Repatha
Kyprolis
Flag link:
The 3 Most Important Drugs in Amgen's Pipeline
The 3 Most Important Drugs in Amgen's Pipeline
Motley Fool
Amgen
ABP 501
Omecamtiv Mecarbil
Kyprolis
Flag link:
5 Key Drugs That Just Won EU Endorsements
5 Key Drugs That Just Won EU Endorsements
Investors.com
Europe
Gilead Sciences
Genvoya
Amgen
Kyprolis
Blincyto
Vertex Pharmaceuticals
Orkambi
Horizon Pharma
Ravicti
Flag link:
FDA Grants Priority Review for Amgen's Supplemental New Drug Application for Expanded Labeling of Kyprolis® (Carfilzomib) in Relapsed Multiple Myeloma
FDA Grants Priority Review for Amgen's Supplemental New Drug Application for Expanded Labeling of Kyprolis® (Carfilzomib) in Relapsed Multiple Myeloma
Yahoo
FDA
Kyprolis
Amgen
Multiple Myeloma
Flag link:
J&J positions blockbuster contender daratumumab for a multiple myeloma showdown
J&J positions blockbuster contender daratumumab for a multiple myeloma showdown
Fierce Biotech
JNJ
daratumumab
Multiple Myeloma
Kyprolis
Amgen
Genmab
elotuzumab
AbbVie
Bristol-Myers Squibb
Flag link:
Dr. Reddy’s Announces Strategic Collaboration with Amgen in India
Dr. Reddy’s Announces Strategic Collaboration with Amgen in India
Yahoo
Dr Reddy's
Amgen
India
Kyprolis
Blincyto
Repatha
Flag link:
Amgen wins new myeloma nod for blockbuster hopeful Kyprolis
Amgen wins new myeloma nod for blockbuster hopeful Kyprolis
Fierce Pharma
Amgen
Multiple Myeloma
Kyprolis
Celgene
Pomolyst
Flag link:
Amgen awaiting FDA decision on cancer drug Kyprolis
Amgen awaiting FDA decision on cancer drug Kyprolis
BioPharma Dive
Amgen
FDA
Kyprolis
Multiple Myeloma
Flag link:
Amgen's Single Most Important FDA Decision of 2015 Is Nearly Here
Amgen's Single Most Important FDA Decision of 2015 Is Nearly Here
Motley Fool
Amgen
FDA
Multiple Myeloma
Kyprolis
Flag link:
Amgen: The Quiet Winner
Amgen: The Quiet Winner
Barron's
Amgen
ASCO
Kyprolis
Flag link:
Amgen Hopes Kyprolis Can Become a Blockbuster
Amgen Hopes Kyprolis Can Become a Blockbuster
Investopedia
Amgen
Kyprolis
Multiple Myeloma
Flag link:
Was Onyx worth it? Amgen's case is looking up as Kyprolis bests Velcade in head-to-head trial
Was Onyx worth it? Amgen's case is looking up as Kyprolis bests Velcade in head-to-head trial
Fierce Pharma
ONYX Pharmaceuticals
Amgen
Velcade
Kyprolis
Multiple Myeloma
Flag link:
Amgen's Kyprolis Outperforms Rival Drug In Study
Amgen's Kyprolis Outperforms Rival Drug In Study
Forbes
Amgen
Kyprolis
Velcade
Takeda
Multiple Myeloma
Flag link:
Amgen And Onyx Announce Detailed Results From Phase 3 ASPIRE Study Of Kyprolis® (Carfilzomib) In Patients With Relapsed Multiple Myeloma
Amgen And Onyx Announce Detailed Results From Phase 3 ASPIRE Study Of Kyprolis® (Carfilzomib) In Patients With Relapsed Multiple Myeloma
Yahoo/PR Newswire
Amgen
ONYX Pharmaceuticals
Kyprolis
Multiple Myeloma
Flag link:
3 Reasons Amgen Inc.'s Stock Could Fall
3 Reasons Amgen Inc.'s Stock Could Fall
Motley Fool
Amgen
Kyprolis
Flag link:
Most Popular News Headlines For Thursday, August 14 2014
Most Popular News Headlines For Thursday, August 14 2014
CP Wire
FDA
Kyprolis
Amgen
asthma
AstraZeneca
AbbVie
orphan drugs
ABT-414
female se
Flag link:
Most popular news headlines for Thursday, August 14 2014
FDA
Kyprolis
Amgen
asthma
AstraZeneca
AbbVie
orphan drugs
ABT-414
female se
Flag link:
Amgen: Why No One Cares About Kyprolis Trial Failure
Amgen: Why No One Cares About Kyprolis Trial Failure
Barron's
Amgen
Kyprolis
Multiple Myeloma
Flag link:
Most Popular News Headlines For Wednesday, August 13 2014
Most Popular News Headlines For Wednesday, August 13 2014
CP Wire
Pfizer
Bristol-Myers Squibb
Eliquis
Belsomra
insomnia
Kyprolis
Aranesp
Amgen
InterMune
Sanofi
Roche
Flag link:

Pages